Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Epigenetics in Drug Discovery

Jun Qi's Biography

Jun Qi, Lead Scientist, Dana Farber Cancer Institute

Dr. Jun Qi is a Lead Scientist in the Medical Oncology Department at Dana-Farber Cancer Institute, the affiliated cancer hospital of Harvard Medical School. Dr. Qi received his BS from Fudan University in China, and obtained his Ph.D. in Chemistry from University of Michigan in 2006, and completed his postdoctoral training at MIT in 2009. Both his Ph.D. and postdoctoral studies have been focused on the total synthesis of natural compounds and the novel synthetic methodology development. Dr. Qi is the lead chemist in Dr. James Bradner’s laboratory at Dana-Farber Cancer Institute. Dr. Qi’s study has been focusing on design and synthesis small molecule inhibitors targeting the gene regulation pathway for cancer therapy. Dr. Qi has discovered a small molecule JQ1 that inhibits one of the bromodomain subfamily, BET bromodomain. Dr. Qi is continuously leading the effort to develop a chemical biology platform to understand the fundamental roles of epigenetic writer, reader and eraser.

Jun Qi Image

Targeting on Epigenetic Proteins for Cancer Therapy

Tuesday, 26 January 2016 at 10:30

Add to Calendar ▼2016-01-26 10:30:002016-01-26 11:30:00Europe/LondonTargeting on Epigenetic Proteins for Cancer TherapyEpigenetics in Drug Discovery in Cambridge, UKCambridge,

Lysine acetylation has emerged as a signalling modification of broad relevance to cellular and disease biology. Targeting acetyl-lysine recognition modules with small molecules have been successfully achieved not only in basic mechanistic understanding, but also promising in human clinic investigation.

Add to Calendar ▼2016-01-26 00:00:002016-01-27 00:00:00Europe/LondonEpigenetics in Drug DiscoveryEpigenetics in Drug Discovery in Cambridge, UKCambridge,